Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896701 · ClinicalTrials.gov registry record
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
A clinical trial of Leukemia, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 451
- Enrollment target
- 2
- Study locations
NCT00896701: Completed study of Leukemia, sponsored by Alliance for Clinical Trials in Oncology.
NCT00896701 is a study of Leukemia that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 451 participants, roughly in line with the 485-participant average among 233 other Leukemia trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896701, a study of Leukemia, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 451 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors predict response in patients previously treated with interleukin-2. PURPOSE: This laboratory study is looking at the relationship between natural killer cells' ability to kill leukemia cells and the outcome of patients with acute myeloid leukemia previously treated with interleukin-2.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER flow cytometry
- OTHER immunologic technique
Study Locations (2)
North Carolina
- Kinston Medical Specialists - Kinston
Ohio
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2004-01 |
| Est. Completion | 2014-04 |
What the finished NCT00896701 record still lists
NCT00896701 is an observational study that tracks outcomes without assigning an intervention. The registered 451 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 485-participant average among 233 other Leukemia trials with a reported enrollment target.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00896701 reports a single indexed study location in North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT00896701 about?
NCT00896701 is a clinical study titled "Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2". RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors predict response in patients previously treated with interleukin-2. PURPOSE: This laboratory study is looking at the relationship between natural killer cells' ability to kill leukemia ...
What is the current status of trial NCT00896701?
This trial is currently completed. The enrollment target is 451 participants. The study started on 2004-01. Estimated completion is 2014-04.
What conditions does trial NCT00896701 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00896701?
The interventions under investigation include: laboratory biomarker analysis (OTHER), flow cytometry (OTHER), immunologic technique (OTHER).
Who is sponsoring clinical trial NCT00896701?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00896701 being conducted?
This trial has 2 study locations across North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00896701's enrollment target sits among peer trials
451 22nd of 233 higher than 212 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia